Select Page

SMU to commence with the Orientation of new students

Media Statement
Date: 01 February 2022
For Immediate Release

The Sefako Makgatho Health Sciences University hereby announces that Orientation for first time entering students will take place from 02 – 04 February 2022. About 1000 students are expected to virtually join the orientation proceedings over a period of three days.

SMU Vice-Chancellor Professor Peter Mbati wishes to thank the students for choosing to study at SMU. “I want to assure our new students that they are joining a University with a
rich history and legacy. Starting from its predecessor universities, SMU is known to have produced men and women who are now playing a significant and prominent role in the
health and other sectors both locally and internationally,” said Prof Mbati.

The Vice-Chancellor further emphasises that the University is right in the middle of a deliberate process to take it to greater heights. “Guided by the University’s 2021-2025 Strategic Plan which serves as our roadmap towards the attainment of our objectives, we are poised to make SMU a leading Regional University as measured by teaching and learning excellence, vibrant impactful research and innovation, post graduate training and excellence in core support activities including ICT, infrastructure and maintenance,” said Prof Mbati.

The University has five (5) Schools which offer a variety of qualifications and boast top academics and National Research Foundation (NRF) rated Researchers.

Issued by Communication and Marketing
For media enquiries, please contact Dr Lusani Netshitomboni Director: Communication and Marketing at
Cell: 0833965885

Media Statement Orientation Days 2022  

Media Statement: Sefako Makgatho Health Sciences University to finalise selection and admission of first entering students for 2022

Media Statement
Date: 18 January 2022
For Immediate Release

Every year, the Sefako Makgatho Health Sciences University receives thousands of applications from prospective students who wish to study at the University. SMU has received more than 44 000 applications for first time entering students for the 2022 academic year while it only has space for approximately1 000 students.

All applications go through a rigorous and competitive selection process and offers are based on the admission requirements of different Schools. This means that attainment of minimum requirements will not automatically guarantee admission to the programmes offered by the University.

The pre-selection and admission of first time entering applicants was conducted in October 2021 by the Selection and Admission Committee of each School and final selection activities will only take place from 21 January 2022 subsequent to the release of the 2021 Grade 12 results.

Those who have applied are urged to check the status of their applications by clicking on the below link and use their student number as well as pin: link:

Successful applicants will be given up to three (3) calendar days to accept or decline the offer online. If they do not respond within the given time, their places will be given to other eligible applicants on the waiting list.

Registration for all First Time Entering Students will then commence on 01 – 04 February 2022. However, those who will not be in a position to finish registration on 04 February due to circumstances beyond their control will be given an opportunity until 07 February 2022 which will serve as the last day.

Registration will be online and students will be able to register for the modules and qualifications they were admitted into. Those who struggle will be assisted on campus at the University sports complex during working hours.

Students can call the following numbers for assistance: 012 521 4204/ 4319/4644/5057.

Issued by Communication and Marketing
For more details, please contact Dr Lusani Netshitomboni (spokesperson) at
Cell: 0833965885

Download Media Statement

Media Statement: Continued student protest at SMU, 08 November 2021

Media Statement
Date: 08 November 2021
For Immediate Release

In the last few days, Management received a set of demands from students residing at University-leased off campus residences, particularly TVL, The Heights and Drie Lillies. The main demand raised is that students should continue to reside at these facilities whose contract with the University expires at the end of 2021.

Students have decided to continue with protest action despite several engagements held with them where the University’s position on the matter was reiterated. Management remains of the firm view that the demand that students be allowed to stay in the University-leased student accommodation facilities beyond the expiry of the signed agreements between the University and these providers, who are not on the approved Panel of Service Providers, cannot be acceded to. What the students want Management to do is to essentially annul its decision that has been approved by Council.

Sadly, the continued student protest will collapse the 2021 academic calendar which has previously been revised again due to staff and student protests on campus earlier in the year. These protests seriously negatively impact on the operations of the University and will affect productivity and the performance of the institution as staff members are also prevented from accessing their offices.

The University rules prohibit any protestors from barricading university entrances. The University Management therefore calls upon protesting students not to prevent those students who want to proceed with their academic studies or staff members who wish to access their offices.

Students are similarly requested to abide by the decision taken by the University as no further extensions of the residences in question would be made as doing so would be illegal and exposes the University to litigation. The University is not in a position to act outside the structures of its Supply Chain Management policies.

Issued by the Communication and Marketing
For more details, please contact Phaladi Seakgwe, email address
Cell: 0790751673

Download Media Statement

Portfolio Committee on Higher Education Science and Innovation upbeat on Developments at SMU

Media Statement
Date: 21 October 2021
For Immediate Release

The Portfolio Committee on Higher Education Science and Innovation conducted an oversight visit at the Sefako Makgatho Health Sciences University on 19 October 2021. In attendance were members of the SMU Council led by Ms Mmanare Mamabolo (Deputy Chairperson of Council), University Management led by the Vice-Chancellor Professor Peter
Mbati, representatives of organised labour and members of the Student Representative Council. Other members of Council in attendance were Mr Thabiso Lekoana and Dr
Mangaliso Mahlaba. The Portfolio Committee was led by its Chairperson, Honorable Nompendulo Mkhatshwa accompanied by Honorable Tebogo Letsie.

The Committee embarked on a tour of the Campus to inspect both infrastructure and research facilities, which included the construction site of the new 2,000 bed student residence, the new boundary wall, NHLS laboratories, Virology/Microbiology laboratories and the new Entrepreneurship Incubation Centre. Following the Campus tour, the Vice-Chancellor made a presentation to the Committee on the University’s five-year Strategic Plan, the progress made as well as prospects and challenges.

As part of securing the future of SMU, Prof Mbati explained to members of the Portfolio Committee that Council had approved a New Business Model to ensure the financial sustainability of the University. Key to this model is increasing the numbers of students to 13,500, exploring new options for student funding, commercialization initiatives and a strong third stream income strategy. Such initiatives are important, according to the Vice-Chancellor, given some of the challenges related to student funding, student debt, backlog
maintenance, and the dire need for additional office space.

Mbati added that the University had made significant strides in creating a new institutional culture preceded by the signing of a Culture Compact by all stakeholders (management, labour and SRC) committing themselves separately and collectively to work for the good of the University. It was also emphasized that the roll out of the Performance Management System has been given sufficient attention for all employees to continuously contribute to a high performance culture. Professor Mbati emphasized the importance of every stakeholder playing their specified roles and not conflating them, in order for SMU to be successful.

Honorable Letsie emphasized the importance of stability on campus as an important recipe for success. He further cautioned that factionalism and lack of cohesion in the governance and management of institutions leads to dysfunctionality and ultimately universities being placed under administration.

The Chairperson of the Parliamentary Committee said it is their responsibility to ensure that the higher education sector delivers on its promises and mandate, and visits such as this provides them with an opportunity to get first-hand experience on how institutions are delivering on their mandates. The Committee was generally upbeat on the progress and developmental trajectory of SMU and promised to embark on future visits to check progress on the many exciting initiatives currently being undertaken at the University.

Issued by the Communication and Marketing
For more details, please contact Odette Ramsingh, email address
Phone 012 521 3383/4707 Cell: 0824164932

Download statement:

Media Statement Portfolio Committee on Higher Education Science and Innovation Upbeat about developments at SMU

Sinovac, China and Partner Numolux, South Africa Launching Paediatric Covid-19 Vaccine Trial (The Pedcoronavac Study) at Sefako Makgatho Health Sciences University

Numolux Group (Pty) Ltd of Pretoria is the authorized representative in South Africa of SINOVAC Life Sciences Co., Ltd., a subsidiary of the SINOVAC Biotech Ltd. (“SINOVAC”) of Beijing, China. SINOVAC and Numolux announced that they are ready with its partners to launch a Phase III pediatric COVID-19 vaccine study on 10 September with the first child to be vaccinated at the MeCRU Clinical Research Unit, based at the Sefako Makgatho Health Sciences University (SMU), South Africa.

The study is a Multi-center, Randomized, Double-blind, Placebo-controlled Phase Ⅲ Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of SINOVAC Inactivated COVID-19 Vaccine (CoronaVac®) in children and adolescents aged 6 months to 17 years. The primary objective of the study is to evaluate the efficacy of two doses of CoronaVac® against confirmed symptomatic COVID-19 cases in children and adolescents aged 6 months to 17 years. Efficacy will also be evaluated against hospitalization and severe COVID-19 cases.

The study worldwide will enroll 14 000 children and adolescents in various pediatric age group cohorts across 5 countries (South Africa, Chile, Philippines, Malaysia and Kenya). Numolux has partnered with 7 clinical research sites across South Africa to enroll 2000 participants from 6 months to 17 years.

Participants in the trial will receive 2 doses of CoronaVac® or placebo 28 days apart. Efficacy assessments to include the surveillance for COVID-19 like symptoms and the laboratory confirmation of SARS-CoV-2 infection by RT-PCR. Any confirmed COVID-19 case will be followed by the investigators until resolution. Whole viral genome sequencing to detect mutations or variants of concern among all the confirmed COVID-19 cases during the trial will be done. Interim analysis will be done when 47 COVID-19 cases have been reported. Safety will be evaluated in terms of solicited local and systemic adverse events during 7 days following vaccination and of unsolicited adverse events during 28 days post-vaccination. Occurrence and relationship of serious adverse events will be monitored from first dose to 12 months after the last dose. Humoral immune response across a subset of all pediatric age group cohorts will be evaluated and cell mediated immune response in a subset of vaccinated participants in Chile will be investigated.

In South Africa, the trial has received South African Health Products Regulatory Authority (SAHPRA), Pharma Ethics and SMUREC approval and is listed on the South African Clinical Trial Registry (Identification number DOH-27-082021-6331).

This study has public health importance globally because a vaccine that prevents COVID-19 disease and transmission in pediatrics would be a crucial tool to assist in curbing the pandemic. Although children and adolescents have a milder form of the disease than adults, they remain susceptible to infection and severe manifestations across all ages.


SINOVAC is committed to the research and development of a safe and effective vaccine that protects people of all ages and comorbidities against COVID-19.


About Sinovac COVID19 Vaccine: CoronaVac®


CoronaVac® is an inactivated SARS-COV-2 vaccine manufactured by SINOVAC Life Sciences Co., Ltd., a subsidiary of the SINOVAC Biotech Ltd., a leading provider of biopharmaceutical products in China.


CoronaVac® received validation from the western science establishment in May 2020 when Science Journal published results of the pre-clinical studies, and in Nov 2020 Lancet published the Phase I/II study results of CoronaVac® in adults followed by a paper in Lancet in July 2021 of the Phase Ⅲ study in conducted in Turkey showing high efficacy (83.5%) against symptomatic PCR confirmed cases with good safety and tolerability, a real-world study from Chile published in the NEJM 02 Sep. 2021 showing 65.9% efficacy of the vaccine in preventing COVID-19 infection in adults and 87.5% in preventing hospitalizations, 90.3% (95% CI, 89.1 to 91.4) for the prevention of ICU admission, and 86.3% (95% CI, 84.5 to 87.9) for the prevention of Covid-19–related death. The Phase I/II study in children has been conducted in China and the results have been published in the Lancet, 28 June 2021.


CoronaVac® is currently approved for emergency use or marketing use with condition in adults in nearly 50 countries worldwide, as well as WHO, and approved for emergency use in children in China on 28 May 2021. CoronaVac® also received EUA/Section 21 approval from SAHPRA on 01 July 2021.


About the Numolux Group (Pty) Ltd


The Numolux group, based in Pretoria, South Africa have been providing advanced and sustainable health solutions to both the public and private sector, locally and internationally, since 2017. Numolux, together with its alliance partners, identifies latent needs with solutions for Hospital Infrastructure, Health Mobile Units, Adaptive Diagnostic Devices, Military Medical Equipment, Rapid Tests, Pharma Products and Vaccines. The CEO of the Numolux Group, Mr Hilton Klein, made the following statement and I quote “The children of Africa are the future of Africa and something must be done to protect the future of Africa against the deadliest pandemic the world has ever seen. Numolux Group has joined Sinovac in the fight against this deadly monster to ensure that the children of Africa have access to a safe and effective children’s vaccine to protect them against COVID-19. Numolux has declared war against this deadly virus and we will do everything in our power to ensure we protect the future of the African children.”


Partners of Numolux Group of companies include Ardent Consulting, providing scientific and technical expertise, and Numolux-Curanto Pharma assisting with regulatory applications. Numolux is the authorized representative of Sinovac Life Sciences in South Africa.


The official launch of the trial , and vaccination of the first participant will take place on: Date: Friday, 10 September 2021
Time: 9am – 11am; MEDIA BRIEFING at 11h30
Venue: MeCRU Research Unit at the Sefako Makgatho Health Sciences University. Tshwane Gauteng


Any media interested in attending the event, please inform us:
Via email:
For any media enquiries please contact Dr Eric Pule, email address, Phone 012 521 4563 Cell: 0763723964


Sefako Makgatho Health Sciences University to broadcast its virtual 2021 Open days

Sefako Makgatho Health Sciences University to broadcast its virtual 2021 Open days

Media Statement
Date: 21 July 2021
For Immediate Release

The Sefako Makgatho Health Sciences University will host Open Days virtually from 22 to 23 July 2021 due to the unusual challenges of Covid-19. Prospective students are encouraged to follow the Open Days broadcasts by logging in to the university website and also download the SMU prospectus to see all available qualifications offered by the University.

SMU boasts top academics and researchers who are rated by the National Research Foundation and respected in their various fields of expertise. These dedicated men and women go out of their way to help the students through their journey as they develop to be full professionals that are expected to make a meaningful contribution in addressing the health challenges and needs of the country upon completion of their studies.

SMU offers a variety of qualifications in the following five schools:

  • School of Medicine
  • School of Science and Technology
  • School of Health Care Sciences
  • School of Oral Health sciences
  • School of Pharmacy

The university has already received over 30 000 applications from prospective students and would like to encourage others not to waste time and apply. The applications for 2022 will close on 30 July 2021 after they were extended previously.

Issued by the Marketing & Communication
For more details, please contact Dr Eric Pule, email address
Phone: 012 521 4563 Cell: 0635035587.

Download Media Statement – 2021 Open Days